Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Improved DNA vaccine plasmids are disclosed that contain novel immunostimulatory RNA compositions. The improved plasmids eliminate all extraneous sequences, incorporate a novel antibiotic free short RNA based selectable marker, increase eukaryotic expression using a novel chimeric promoter, improve yield and stability during bacterial production, and improve immunostimulation. These vectors are utilized in immunization to elicit improved immune responses or therapy to induce type 1 interferon production.
Core Innovation
The invention provides minimized DNA vaccine and gene-therapy vectors for antibiotic marker-free selection and propagation of covalently closed, super-coiled DNA replicons in bacterial cells. The system utilizes an RNA-OUT antisense sequence to repress an RNA-IN-controlled chromosomal selectable marker, such as levansucrase, thereby enabling sucrose-based selection without antibiotic resistance markers. Selected transformed cells are subsequently propagated to accumulate the plasmid DNA replicon.
Disclosed vector configurations incorporate a gene of interest along with encoded immunostimulatory RNA elements, including composite eRNA41H comprising eRNA11a and adenoviral VARNAI. These elements synergistically activate RIG-I and MDA5 to enhance antigen expression and immunostimulatory activity comparable to kanamycin-marker controls. In vivo evaluations in mice demonstrate increased anti-hemagglutinin immune responses and an induced TH1 bias using these antibiotic marker-free DNA replicons.
Claims Coverage
The independent claims cover three inventive features relating to antibiotic marker-free selection and propagation of covalently closed, super-coiled DNA replicons in bacterial cells.
RNA-OUT-mediated sucrose selection and replicon propagation
An antibiotic marker-free, covalently closed, super-coiled DNA replicon comprises an RNA-OUT antisense gene that hybridizes with an RNA-IN sequence and ATG initiation site, reducing translation of an RNA-IN-controlled levansucrase gene to enable sucrose-based selection and replicon propagation.
Replicon comprising eRNA11a and VARNAI
An antibiotic marker-free DNA replicon comprises a gene of interest, eRNA11a, VARNAI, and an RNA-OUT antisense gene, which functions with bacterial host cells expressing an RNA-IN-controlled selectable chromosomal gene for antibiotic marker-free selection and propagation.
RNA-OUT antisense sequence targeting an RNA-IN-controlled selectable gene
An antibiotic marker-free DNA replicon comprises a gene of interest and an RNA-OUT antisense sequence featuring an internal insertion sequence 10-derived portion, an RNA-OUT promoter, and a region complementary to an RNA-IN sequence and terminator, targeting the ribosomal binding site and ATG initiation site for selection and replicon accumulation.
Together, the independent claims cover antibiotic marker-free selection and propagation systems for super-coiled DNA replicons using RNA-OUT antisense RNA and RNA-IN-controlled chromosomal selectable genes, including levansucrase-mediated sucrose selection and configurations comprising eRNA11a and VARNAI.
Stated Advantages
The composite eRNA41H synergistically activates RIG-I and activates MDA5.
Immunostimulatory RNA elements enhance antigen expression, and mouse studies report increased anti-HA responses and a TH1 bias.
The RNA-OUT selection system supports plasmid fermentation yielding high quantities with high supercoiled-monomer quality.
Sucrose-based selection demonstrates robust recovery, and vaccine-plasmid ligations yield high proportions of correct colonies with cassette functionality in either orientation.
RNA-OUT vectors maintain antigen expression and immunostimulatory activity comparable to kanamycin-marker controls.
A mitochondrial R-region vector increases anti-HA immune responses in mice, and VARNA increases promoter-driven expression of the gene of interest.
Documented Applications
Use in DNA vaccine and gene-therapy vectors.
Antibiotic marker-free selection and propagation of covalently closed, super-coiled DNA replicons in bacteria to produce biological molecules, including plasmids, proteins, RNAs, nucleotides, and biosynthetic pathway products or intermediates.
Construction and production of DNA-vaccine vectors encoding H5 or H5N1 influenza virus hemagglutinin.
Application of mitochondrial R-region DNA-vaccine vectors in evaluations of anti-HA immune responses in mice.
Interested in licensing this patent?